SciSparc Ltd. (SPRC), a Tel Aviv-based clinical-stage pharmaceutical company developing cannabinoid-based therapies, has suffered one of the most severe collapses on the Nasdaq in recent weeks. With the share price near $1.09 after a steep sell-off, investors are asking whether the stock can recover to $1.50. This article examines what that level represents and the factors that could support or block such a move.
SciSparc is a clinical-stage biopharmaceutical company and an extremely small public issuer. Its market capitalization has fallen to roughly $0.6 million to $0.8 million, and it is effectively uncovered by sell-side research. The few analysts historically listed as covering the company have not published current, attributable price targets, so no meaningful analyst consensus exists. For that reason, this article uses a fallback approach: the $1.50 level is drawn from technical and psychological milestones rather than from analyst estimates.
The figure sits roughly midway between the recent crash low near $1.07 and the $2.00 level where the stock briefly stabilized on October 15, 2026, and it sits comfortably above the $1.00 minimum bid price threshold used by Nasdaq. It should be understood as a recovery objective observed in public market structure, not a published forecast or a 12-month research target.
SciSparc closed near $1.09 on October 23, 2026, down about 97% from its 52-week high of roughly $37.90. Reaching $1.50 would require a gain of approximately 38%, which is a substantial move even for a stock that routinely trades with double-digit daily swings. The path would likely depend less on steady fundamental progress and more on the resolution of near-term stress: the stock fell sharply in mid-October, including a 44.9% single-day decline on unusually heavy volume, before sliding further.
Fundamentally, SciSparc generates minimal revenue (roughly $0.86 million over the trailing twelve months) and posts significant net losses, so the company remains reliant on capital raises to fund development of SCI-110 (for Tourette syndrome and Alzheimer's-related agitation) and SCI-210 (for autism spectrum disorder and status epilepticus). Any sustained recovery toward $1.50 would require both a stabilization in trading conditions and renewed confidence in the clinical pipeline or the company's balance sheet.
The stock's recent crash low near $1.07 marks initial support, with the $1.00 round number acting as a key psychological floor and the Nasdaq minimum bid threshold. On the upside, $1.50 is the first notable recovery level, followed by the $2.00 area where shares stabilized on October 15, and then the pre-crash consolidation zone between roughly $3.60 and $4.70. The 52-week high near $37.90 reflects how far the stock has fallen rather than a realistic near-term objective. The persistent downtrend means the stock must first establish durable support before any recovery level becomes meaningful.
Because the $1.50 target is a technical recovery level rather than an analyst target, it carries no formal research horizon. Investors should treat it as a near-term market-structure objective rather than a 12-month forecast. Key items to watch include updates on the Nasdaq listing compliance process, any new financing or dilution announcements, clinical trial readouts for SCI-110 and SCI-210, and quarterly financial filings. Given the stock's volatility, price action and trading volume around the $1.00 and $1.50 levels will also be important signals.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a highly volatile, thinly traded name such as SciSparc, automated monitoring can help traders spot shifting trends and manage positions more efficiently than manual review alone. The tool is designed to surface opportunities and flag deteriorating patterns as they emerge. Traders looking to navigate fast-moving situations can explore these AI-generated signals to complement their own research.
SciSparc (SPRC) reaching $1.50 would represent a roughly 38% recovery from its recent price near $1.09. Because no credible, current analyst price targets exist for this micro-cap, the $1.50 level is a technical recovery objective rather than a consensus forecast. The strongest potential supports are the clinical pipeline and a resolution of the Nasdaq listing overhang, while the principal obstacles are listing risk, cash burn, potential dilution, and binary trial outcomes. Investors should monitor Nasdaq compliance, financing activity, and clinical updates before drawing any conclusions about the stock's path. No outcome is guaranteed, and this analysis does not constitute a prediction or a recommendation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SPRC has been loosely correlated with GYRE. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRC jumps, then GYRE could also see price increases.
| Ticker / NAME | Correlation To SPRC | 1D Price Change % | ||
|---|---|---|---|---|
| SPRC | 100% | -6.34% | ||
| GYRE - SPRC | 38% Loosely correlated | +1.86% | ||
| MTNB - SPRC | 36% Loosely correlated | +3.00% | ||
| ALZN - SPRC | 31% Poorly correlated | -4.84% | ||
| NCEL - SPRC | 30% Poorly correlated | +5.36% | ||
| NKTX - SPRC | 30% Poorly correlated | +1.68% | ||
More | ||||